Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile.
about
Ghrelin for the management of cachexia associated with cancerLoss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatmentSynthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects.Therapeutic Potential of Targeting the Ghrelin Pathway.Moving on up: the Journal of Cachexia, Sarcopenia and Muscle.Rikkunshito, a ghrelin potentiator, ameliorates anorexia-cachexia syndromeDeranged iron status in psoriasis: the impact of low body mass.Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.Increased Ghrelin but Low Ghrelin-Reactive Immunoglobulins in a Rat Model of Methotrexate Chemotherapy-Induced Anorexia.From Belly to Brain: Targeting the Ghrelin Receptor in Appetite and Food Intake Regulation.Cancer cachexia, recent advances, and future directions.Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC.Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer-going beyond PSA and imaging, a systematic literature review.The wasting continuum in heart failure: from sarcopenia to cachexia.Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy.The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia.Palliative Pharmacotherapy: State-of-the-Art Management of Symptoms in Patients With Cancer.Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis.Novel therapeutic options for cachexia and sarcopenia.Relamorelin for the treatment of gastrointestinal motility disorders.Oncology Update: Anamorelin.Anorexia of ageing: a key component in the pathogenesis of both sarcopenia and cachexia.Moving upwards - the journal of cachexia, sarcopenia and muscle in 2016.Novel mechanism of ghrelin therapy for cachexia.Oodles of opportunities: the Journal of Cachexia, Sarcopenia and Muscle in 2017.Research priorities in cancer cachexia: The University of Rochester Cancer Center NCI Community Oncology Research Program Research Base Symposium on Cancer Cachexia and Sarcopenia.Recent advances in pharmacological, hormonal, and nutritional intervention for sarcopenia.Quinolones Modulate Ghrelin Receptor Signaling: Potential for a Novel Small Molecule Scaffold in the Treatment of Cachexia.
P2860
Q26471773-2641A59B-30AD-4D7E-9686-5F233A06498FQ26775254-0A9798A7-CED8-4B0D-9508-B620262C3735Q33565870-D4F8FD9E-A0AC-4E54-88C7-5398270AA636Q33624632-61638568-AB7A-4C9C-8A56-3532B49BF580Q34495485-C589BFF9-6867-454E-B861-7D5204CA1445Q34669261-460A48E0-57CE-4E8F-BC44-A62F9763B568Q36349371-C1BD3766-7222-43FB-8C7F-D7352A4E08FAQ37030111-D72E648E-C6C5-45AB-BDFB-CF83AE9DDB53Q37124526-6AA91E1F-68BF-49A9-AD53-3D720E5A5F2FQ37690695-667CFBE5-250B-4D43-B8E5-2D6ACFDD3BEDQ38393457-C804A3DC-3774-4D57-883C-A970C2B65FB6Q38462047-49C2B03E-C7EB-48D6-A617-AC64E0B4F21FQ38555581-486014B1-5A6A-4DBB-9EF0-C2A50BDDD13BQ38564746-836E32AC-6993-439F-9C8C-19DD5902B41FQ38636513-4C166920-8769-4FF6-8DAE-78FA69231E31Q38670238-28A50C52-C247-4AAE-AC6D-C8502728EEF3Q38672357-4AB18341-70DC-4953-8327-B8D36AE1CFF0Q38772058-9C430293-3BB7-48EA-9F8C-BFE8EA9C274DQ38887581-4339AC7D-4C71-4BBF-89F9-5A3C533B05EAQ39150802-C3B19B40-4D94-48A1-9913-0717B815116EQ41511150-57D0EFD2-4572-469B-B89F-7323D8A9ABF7Q42348565-46041610-F5B5-4472-B307-5CCD1B5381A6Q42398018-84B411F6-73AA-4EA3-B435-6212451D9FD0Q43142441-87139DA5-9694-4B1B-A274-35FF2F6C87B1Q46213438-EC60BEC1-C875-4ED5-B425-DD8994AAB253Q46621430-05524E7C-6731-41E5-90B4-2AE77ED5584FQ47636085-A209BAE7-E86B-4D6B-B1E3-80C90A697F68Q55646811-0F18768F-A2A9-4E79-AE5D-5DA90307B1FB
P2860
Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Anamorelin HCl (ONO-7643), a n ...... syndrome: preclinical profile.
@en
Anamorelin HCl (ONO-7643), a n ...... syndrome: preclinical profile.
@nl
type
label
Anamorelin HCl (ONO-7643), a n ...... syndrome: preclinical profile.
@en
Anamorelin HCl (ONO-7643), a n ...... syndrome: preclinical profile.
@nl
prefLabel
Anamorelin HCl (ONO-7643), a n ...... syndrome: preclinical profile.
@en
Anamorelin HCl (ONO-7643), a n ...... syndrome: preclinical profile.
@nl
P2093
P2860
P1476
Anamorelin HCl (ONO-7643), a n ...... syndrome: preclinical profile.
@en
P2093
Claudio Pietra
Elizabeth Manning Duus
Masashi Minami
Naoko Tazawa-Ogata
Robert Northrup
Xia Yuanfeng
Yasuhiro Takeda
P2860
P2888
P304
P356
10.1007/S13539-014-0159-5
P577
2014-09-30T00:00:00Z
P5875
P6179
1045660133